1. The Next Challenge: From Factory to Self-Production

In Article 2, we celebrated the victory over contaminated plasma, thanks to recombinant DNA “bio-factories.” However, this solution required patients to continue receiving regular infusions of the medication.

The ultimate goal of science was what we call in vivo gene therapy (in the body): delivering a healthy copy of the F8 gene to the patient’s cells, allowing them to become the source of continuous Factor VIII production themselves.

The problem was delivery. How to carry the gene “recipe” (a piece of DNA) to the liver, where clotting is regulated, without it being destroyed or causing harm?

2. Demystifying the Biological “Trojan Horse”

For many, the idea of injecting a virus into the body is terrifying. It is crucial to understand that the AAV Vector (Adeno-Associated Virus) used in gene therapy is not the virus that causes the flu or serious diseases; it is a naturally harmless virus.

Science performed what we call “domestication”:

  1. Disarmament: The AAV’s original, pathogenic (disease-causing) genetic material is removed. The virus is left with only its protective “shell.”
  2. Filling: The empty space inside the viral shell is filled with the healthy, functional copy of the human F8 gene.
  3. Addressing: The virus’s shell acts as a GPS system, being naturally attracted to certain cells, such as liver hepatocytes.

In this way, the AAV transformed into a biological “postman,” a capsule empty of threat, but full of a vital instruction.

3. The Delivery Mechanism: AAV vs. CRISPR

This is the point that generates the most confusion: Current Gene Therapy for Hemophilia (AAV-based) is not genetic editing (CRISPR).

  • AAV Vector (The Postman): The AAV delivers the F8 gene into the cell’s nucleus. This new copy of the gene functions alongside the patient’s original DNA. It does not cut, does not edit, and does not alter the patient’s original genetic code. It simply adds a functional instruction.

  • CRISPR (The Scissors - Future): CRISPR (which we will address in Article 5) is a tool that permanently edits or corrects the DNA. AAV is less invasive, but the instruction it delivers tends to degrade over time (although many patients maintain stable levels for years).

The AAV strategy is one of “addition” and has been tested in Phase 3 clinical trials with very promising results.

4. The Hope of a Life Without Infusions

The AAV is infused once into the bloodstream. It travels to the liver, enters the cells, and delivers the healthy copy of the gene. The liver cells then begin producing Factor VIII, reducing or eliminating the need for regular infusions.

This technology, today, is at the heart of multi-million dollar drugs, representing the hope of a “functional cure”—the ability to live without the constant burden of treatment. But like any breakthrough, it raises ethical and financial questions that we will explore in depth.

➡️ The Continuation of the Series

The ‘Postman’ technology is on the market. In the next article, we will analyze the actual drugs that use AAV and the dilemma of their cost.

🔗 References